The company capped it off with news that a private company that it owns a significant stake in had presented pre-clinical data that showed its distinct platform technology has the potential to reduce the risk of an infection with Influenza virus H1N1 and could also potentially treat additional cold viruses.
That company is
Polyrizon Ltd., of which Medigus owns a 35.86% of its share capital.
The Health Care seed-stage company develops novel biological-gels and in
a media release for investors on Friday, Medigus stated that the data that Polyrizon shared from its cell-culture study confirmed that its innovative product works in a dose-dependent manner to effectively reduce the infection of cells from the influenza virus H1N1.
Polyrizon’s new product candidate protects the nasal cavity and the respiratory tract. In its H1N1 studies, product candidates demonstrated high efficacy by preventing the influenza virus from affecting epithelial host cells and inhibit cells death.
It was also pointed out that use of the Capture and Contain platform technology would help provide a boost in Polyrizon’s product line extended against flu and cold viruses along with a variety of different respiratory viruses.
Medigus is a technology company that works with advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions. It acquired
a private company earlier this month that produces branded products sold at stores like
Walmart,
Target,
Staples,
Kroger, and others.
For more details on the company, visit
medigus.com.
FULL DISCLOSURE: Medigus Ltd. Is a client of Stockhouse Publishing.